Genetic Medicines to Treat Cardiovascular Disease

Genetic medicines are transforming how we treat cardiovascular disease, unlocking opportunities to correct heart and vascular disorders in ways once thought impossible. Basic scientists, clinicians, industry leaders, and innovators will convene at Genetic Medicines to Treat Cardiovascular Disease to explore how gene therapy, RNA-based approaches, gene editing, and advanced disease models are driving these breakthroughs. The program blends cutting-edge science and real-world translation. Sessions will highlight advances in mechanisms underlying cardiovascular genetics, therapeutic target identification, and novel delivery technologies. Plenary speakers and abstract-selected talks will connect foundational research with translational strategies, offering attendees a holistic view of where the field is headed. Additionally, the program will feature panel discussions focused on the steps leading from basic discovery to translation, commercialization, FDA approval, and navigating the venture capital landscape. Key topics include challenges and opportunities in delivery, efficacy, safety, trial design, long-term and off-target effects of therapies, and ethical and regulatory considerations. The program also includes lessons from preclinical and clinical trials, and professional development challenges for early-career researchers. This meeting also emphasizes interdisciplinary collaboration and career development. Career roundtables provide trainees and early-career investigators with direct access to leaders from academia, biotech, and industry for guidance on scientific and professional growth.

Topics: Metabolism, Cardiovascular Genetics, RNA Metabolism, Genetics, Geonomics, Stem Cell Biology, Translational Research, Gene Therapy, RNA Therapeutics, Biotech Innovation